Published: Mar 17, 2021
CHATSWORTH, Calif., March 17, 2021 /PRNewswire/ Monocent Inc., (Monocent) is pleased to announce the COFEPRIS authorization of their SARS-CoV2 Antigen Rapid test System for detection of COVID-19 infection. The Monocent antigen test is a lateral flow test that provides results in just 15-minutes, without the use of any laboratory equipment. A collection of 3
rd party clinical evaluation studies from US, UK, Mexico, Columbia, India and China have shown the test to have 98% sensitivity and 100% specificity when compared to RT-PCR, making it ideal for large-scale, cost effective testing programs.
The Monocent Antigen Test is one component of Monocent s comprehensive COVID-19 testing solution. The test is paired with a complimentary, cutting-edge, HIPAA compliant technology platform, Rymedi. Rymedi s intuitive software will allow test administrators to securely send results to an individuals mobile wallet and display as a scannable QR code. Positiv